NYSE:CHEChemed Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Chemed Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $511.92 +4.49 (+0.88 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$507.31Now: $511.92▼$512.7350-Day Range$443.46MA: $470.46▼$507.4352-Week Range$330.01Now: $511.92▼$513.75Volume44,063 shsAverage Volume71,028 shsMarket Capitalization$8.15 billionP/E Ratio32.18Dividend Yield0.25%Beta0.71 ProfileAnalyst RatingsAdvanced ChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates through two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned and independent contractors, and franchised locations. Chemed Corporation was founded in 1970 and is headquartered in Cincinnati, Ohio.Read More Beat the Market (BTM) Rank™ 1.5 Analyst's Opinion Consensus RatingChemed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $515.00, Chemed has a potential upside of 0.6% from its current price of $511.92.Amount of Analyst CoverageChemed has received no research coverage in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesChemed has received 301 “outperform” votes. (Add your “outperform” vote.)Underperform VotesChemed has received 362 “underperform” votes. (Add your “underperform” vote.)Community SentimentChemed has received 54.60% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Chemed and other stocks. Vote “Outperform” if you believe CHE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CHE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 3.3 Dividend Strength Dividend YieldChemed has a dividend yield of 0.25%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthChemed has been increasing its dividend for 11 years.Dividend CoverageThe dividend payout ratio of Chemed is 9.18%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Chemed will have a dividend payout ratio of 7.28% next year. This indicates that Chemed will be able to sustain or increase its dividend. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Chemed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,215,473.00 in company stock.Percentage Held by InsidersOnly 3.96% of the stock of Chemed is held by insiders.Percentage Held by Institutions88.73% of the stock of Chemed is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Chemed are expected to grow by 8.92% in the coming year, from $16.14 to $17.58 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chemed is 32.18, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 17.12.Price to Earnings Ratio vs. SectorThe P/E ratio of Chemed is 32.18, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.40.Price to Earnings Growth RatioChemed has a PEG Ratio of 3.26. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioChemed has a P/B Ratio of 10.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.5Community Rank: 2.3Dividend Strength: 3.3Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.75 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Home health care services Sub-IndustryHealth Care Services SectorMedical Current SymbolNYSE:CHE Previous Symbol CUSIP16359R10 CIK19584 Webwww.chemed.com Phone513-762-6690Debt Debt-to-Equity Ratio0.14 Current Ratio0.59 Quick Ratio0.57Price-To-Earnings Trailing P/E Ratio32.18 Forward P/E Ratio31.72 P/E Growth3.26 Sales & Book Value Annual Sales$1.94 billion Price / Sales4.20 Cash Flow$17.39 per share Price / Cash Flow29.43 Book Value$47.16 per share Price / Book10.85Profitability EPS (Most Recent Fiscal Year)$13.95 Net Income$219.92 million Net Margins12.99% Return on Equity36.71% Return on Assets20.52%Miscellaneous Employees16,641 Outstanding Shares15,920,000Market Cap$8.15 billion Next Earnings Date11/3/2020 (Estimated) OptionableOptionable $511.92 +4.49 (+0.88 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CHE News and Ratings via Email Sign-up to receive the latest news and ratings for CHE and its competitors with MarketBeat's FREE daily newsletter. Chemed (NYSE:CHE) Frequently Asked Questions How has Chemed's stock been impacted by COVID-19 (Coronavirus)? Chemed's stock was trading at $414.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CHE shares have increased by 23.6% and is now trading at $511.92. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Chemed? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Chemed. When is Chemed's next earnings date? Chemed is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Chemed. How were Chemed's earnings last quarter? Chemed Co. (NYSE:CHE) released its earnings results on Wednesday, July, 29th. The company reported $4.41 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $3.75 by $0.66. The firm had revenue of $502.20 million for the quarter, compared to the consensus estimate of $522.90 million. Chemed had a net margin of 12.99% and a return on equity of 36.71%. The firm's revenue for the quarter was up 6.0% on a year-over-year basis. During the same period in the prior year, the company posted $3.36 earnings per share. View Chemed's earnings history. How often does Chemed pay dividends? What is the dividend yield for Chemed? Chemed announced a quarterly dividend on Tuesday, May 19th. Investors of record on Thursday, May 28th will be paid a dividend of $0.32 per share on Wednesday, June 17th. This represents a $1.28 annualized dividend and a yield of 0.25%. The ex-dividend date of this dividend is Wednesday, May 27th. View Chemed's dividend history. What guidance has Chemed issued on next quarter's earnings? Chemed issued an update on its FY20 earnings guidance on Wednesday, July, 29th. The company provided EPS guidance of $16.20-16.40 for the period, compared to the Thomson Reuters consensus estimate of $16.13. What price target have analysts set for CHE? 4 analysts have issued 12-month target prices for Chemed's shares. Their forecasts range from $490.00 to $535.00. On average, they expect Chemed's share price to reach $515.00 in the next twelve months. This suggests a possible upside of 0.6% from the stock's current price. View analysts' price targets for Chemed. Has Chemed been receiving favorable news coverage? Media headlines about CHE stock have been trending very positive this week, InfoTrie reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Chemed earned a daily sentiment score of 4.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Chemed. Are investors shorting Chemed? Chemed saw a decrease in short interest in July. As of July 31st, there was short interest totaling 177,700 shares, a decrease of 24.8% from the July 15th total of 236,200 shares. Based on an average daily volume of 109,700 shares, the days-to-cover ratio is presently 1.6 days. Approximately 1.2% of the company's stock are sold short. View Chemed's Short Interest. Who are some of Chemed's key competitors? Some companies that are related to Chemed include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), R1 RCM (RCM), MEDNAX (MD), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG). View all competitors. What other stocks do shareholders of Chemed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include AT&T (T), Home Depot (HD), Altria Group (MO), Target (TGT), Verizon Communications (VZ), AbbVie (ABBV), Boeing (BA), CVS Health (CVS), Chevron (CVX) and Johnson & Johnson (JNJ). Who are Chemed's key executives? Chemed's management team includes the following people: Mr. Kevin J. McNamara, CEO, Pres & Director (Age 65)Mr. David P. Williams, Exec. VP & CFO (Age 58)Ms. Naomi C. Dallob, VP, Chief Legal Officer & Sec. (Age 65)Mr. Spencer S. Lee, Exec. VP (Age 63)Mr. Nicholas Michael Westfall, Exec. VP (Age 40) What is Chemed's stock symbol? Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE." Who are Chemed's major shareholders? Chemed's stock is owned by many different retail and institutional investors. Top institutional investors include Riverbridge Partners LLC (2.12%), Fisher Asset Management LLC (1.14%), TimesSquare Capital Management LLC (1.14%), Copeland Capital Management LLC (0.67%), First Trust Advisors LP (0.51%) and Boston Trust Walden Corp (0.47%). Company insiders that own Chemed stock include Andrea R Lindell, David Patrick Williams, Donald E Saunders, Frank E Wood, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee, Thomas P Rice and Walter L Krebs. View institutional ownership trends for Chemed. Which institutional investors are selling Chemed stock? CHE stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Boston Trust Walden Corp, Riverbridge Partners LLC, Fort Washington Investment Advisors Inc. OH, First Trust Advisors LP, Russell Investments Group Ltd., TimesSquare Capital Management LLC, and Raymond James Financial Services Advisors Inc.. Company insiders that have sold Chemed company stock in the last year include Andrea R Lindell, David Patrick Williams, Donald E Saunders, Frank E Wood, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Patrick P Grace, Spencer S Lee, and Walter L Krebs. View insider buying and selling activity for Chemed. Which institutional investors are buying Chemed stock? CHE stock was acquired by a variety of institutional investors in the last quarter, including Trinity Street Asset Management LLP, Raymond James & Associates, Princeton Portfolio Strategies Group LLC, Contravisory Investment Management Inc., Envestnet Asset Management Inc., UBS Group AG, Swiss National Bank, and Vident Investment Advisory LLC. View insider buying and selling activity for Chemed. How do I buy shares of Chemed? Shares of CHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Chemed's stock price today? One share of CHE stock can currently be purchased for approximately $511.92. How big of a company is Chemed? Chemed has a market capitalization of $8.15 billion and generates $1.94 billion in revenue each year. The company earns $219.92 million in net income (profit) each year or $13.95 on an earnings per share basis. Chemed employs 16,641 workers across the globe. What is Chemed's official website? The official website for Chemed is www.chemed.com. How can I contact Chemed? Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The company can be reached via phone at 513-762-6690. This page was last updated on 8/8/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
